Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021

Imagem de Miniatura
Arquivos
art_BOLLYKY_Pandemic_preparedness_and_COVID19_an_exploratory_analysis_of_2022.PDF (2.54 MB)
Citações na Scopus
169
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
BOLLYKY, Thomas J.
HULLAND, Erin N.
BARBER, Ryan M.
COLLINS, James K.
KIERNAN, Samantha
MOSES, Mark
PIGOTT, David M.
JR, Robert C. Reiner
SORENSEN, Reed J. D.
ABBAFATI, Cristiana
Citação
LANCET, v.399, n.10334, p.1489-1512, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background National rates of COVID-19 infection and fatality have varied dramatically since the onset of the pandemic. Understanding the conditions associated with this cross-country variation is essential to guiding investment in more effective preparedness and response for future pandemics. Methods Daily SARS-CoV-2 infections and COVID-19 deaths for 177 countries and territories and 181 subnational locations were extracted from the Institute for Health Metrics and Evaluation's modelling database. Cumulative infection rate and infection-fatality ratio (IFR) were estimated and standardised for environmental, demographic, biological, and economic factors. For infections, we included factors associated with environmental seasonality (measured as the relative risk of pneumonia), population density, gross domestic product (GDP) per capita, proportion of the population living below 100 m, and a proxy for previous exposure to other betacoronaviruses. For IFR, factors were age distribution of the population, mean body-mass index (BMI), exposure to air pollution, smoking rates, the proxy for previous exposure to other betacoronaviruses, population density, age-standardised prevalence of chronic obstructive pulmonary disease and cancer, and GDP per capita. These were standardised using indirect age standardisation and multivariate linear models. Standardised national cumulative infection rates and IFRs were tested for associations with 12 pandemic preparedness indices, seven health-care capacity indicators, and ten other demographic, social, and political conditions using linear regression. To investigate pathways by which important factors might affect infections with SARS-CoV-2, we also assessed the relationship between interpersonal and governmental trust and corruption and changes in mobility patterns and COVID-19 vaccination rates. Findings The factors that explained the most variation in cumulative rates of SARS-CoV-2 infection between Jan 1, 2020, and Sept 30, 2021, included the proportion of the population living below 100 m (5-4% [4-0-7-9] of variation), GDP per capita (4-2% [1-8-6-6] of variation), and the proportion of infections attributable to seasonality (2-1% [95% uncertainty interval 1-7-2-7] of variation). Most cross-country variation in cumulative infection rates could not be explained. The factors that explained the most variation in COVID-19 IFR over the same period were the age profile of the country (46-7% [18-4-67-6] of variation), GDP percapita (3-1%[0-3-8-6] ofvariation), and national mean BMI (1-1%[0-2-2-6] ofvariation). 44-4% (29-2-61-7) of cross-national variation in IFR could not be explained. Pandemic-preparedness indices, which aim to measure health security capacity, were not meaningfully associated with standardised infection rates or IFRs. Measures of trust in the government and interpersonal trust, as well as less government corruption, had larger, statistically significant associations with lower standardised infection rates. High levels of government and interpersonal trust, as well as less government corruption, were also associated with higher COVID-19 vaccine coverage among middle-income and high-income countries where vaccine availability was more widespread, and lower corruption was associated with greater reductions in mobility. If these modelled associations were to be causal, an increase in trust of governments such that all countries had societies that attained at least the amount of trust in government or interpersonal trust measured in Denmark, which is in the 75th percentile across these spectrums, might have reduced global infections by 12-9% (5-7-17-8) for government trust and 40-3% (24-3-51-4) for interpersonal trust. Similarly, if all countries had a national BMI equal to or less than that of the 25th percentile, our analysis suggests global standardised IFR would be reduced by 11-1%. Interpretation Efforts to improve pandemic preparedness and response for the next pandemic might benefit from greater investment in risk communication and community engagement strategies to boost the confidence that individuals have in public health guidance. Our results suggest that increasing health promotion for key modifiable risks is associated with a reduction of fatalities in such a scenario. Funding Bill & Melinda Gates Foundation, J Stanton, T Gillespie, J and E Nordstrom, and Bloomberg Philanthropies.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/48297
Referências
  1. Abascal M, 2015, AM J SOCIOL, V121, P722, DOI 10.1086/683144
  2. Abbey EJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239398
  3. Adamecz-Volgyi A, 2021, SSRN, DOI [10.2139/ssrn.3867690, DOI 10.2139/SSRN.3867690]
  4. Afshin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172277
  5. Aldrich DP, 2015, AM BEHAV SCI, V59, P254, DOI 10.1177/0002764214550299
  6. Anderson CJ, 2003, AM J POLIT SCI, V47, P91, DOI 10.2307/3186095
  7. Barber RM, LANCET
  8. Bargain O, 2020, J PUBLIC ECON, V192, DOI 10.1016/j.jpubeco.2020.104316
  9. Blair RA, 2017, SOC SCI MED, V172, P89, DOI 10.1016/j.socscimed.2016.11.016
  10. Blecher E, 2008, J HEALTH ECON, V27, P930, DOI 10.1016/j.jhealeco.2008.02.010
  11. Bollyky T.J., 2021, FOREIGN AFF
  12. Bollyky TJ., 2021, COUNCIL FOREIGN RELA
  13. Bollyky TJ., 2020, IMPROVING PANDEMIC P
  14. Bosancianu CM, 2020, SOCARXIV, DOI [10.31235/osf.io/ub3zd, DOI 10.31235/OSF.IO/UB3ZD]
  15. Bourdieu P., 1986, HDB THEORY RES SOCIO, P241
  16. Chernozhukov V, 2021, J ECONOMETRICS, V220, P23, DOI 10.1016/j.jeconom.2020.09.003
  17. COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943
  18. Courtemanche C, 2020, HEALTH AFFAIR, V39, P1237, DOI 10.1377/hlthaff.2020.00608
  19. COVID-19 Forecasting Team, LANCET
  20. Crosby S, 2020, THINK GLOBAL HLTH
  21. Daniels ME, 2014, 72 IND TASK FORC
  22. Devine D, 2021, POLIT STUD REV, V19, P274, DOI 10.1177/1478929920948684
  23. Farzanegan M. R, 2021, EFFECT PUBLIC CORRUP, DOI [10.2139/ssrn.3805464, DOI 10.2139/SSRN.3805464]
  24. Fukuyama F, 2020, FOREIGN AFF, V99, P26
  25. Gachter S, 2004, J ECON BEHAV ORGAN, V55, P505, DOI 10.1016/j.jebo.2003.11.006
  26. GHS Index, 2020, US COVID 19 LEAD WOR
  27. GHS Index, 2020, COVID 19 ID MOST VUL
  28. Gilles I, 2011, EUR J EPIDEMIOL, V26, P203, DOI 10.1007/s10654-011-9577-2
  29. Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820002046
  30. Han Q, 2021, PSYARXIV, DOI [10.31234/osf.io/p5gns, DOI 10.31234/OSF.IO/P5GNS]
  31. IHME, 2021, COVID 19 EST HIST TI
  32. Independent Panel for Pandemic Preparedness and Response (Independent Panel), 2021, COVID 19 MAKE IT LAS
  33. Institute for Health Metrics and Evaluation, 2021, EST TOTAL MORT DUE
  34. Josse J, 2016, J STAT SOFTW, V70
  35. Kaiser K-A, 2016, SIN TAX REFORM PHILI
  36. Kandel N, 2020, LANCET, V395, P1047, DOI 10.1016/S0140-6736(20)30553-5
  37. Khan AJ, 2009, B WORLD HEALTH ORGAN, V87, P193, DOI 10.2471/BLT.07.048264
  38. Khosravi M, 2020, ELECTRON J GEN MED, V17, DOI 10.29333/ejgm/7856
  39. Kock RA, 2020, LANCET PLANET HEALTH, V4, pE87, DOI 10.1016/S2542-5196(20)30035-8
  40. Kwon S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24115-7
  41. Landrigan PJ, 2018, LANCET, V391, P462, DOI 10.1016/S0140-6736(17)32345-0
  42. Larson HJ, 2010, JAMA-J AM MED ASSOC, V303, P271, DOI 10.1001/jama.2009.2023
  43. Lee C.T., WORLD SCET, P2021, DOI [10.1101/2021.02.02.21251013, DOI 10.1101/2021.02.02.21251013]
  44. Mallapaty S, 2020, NATURE, V585, P16, DOI 10.1038/d41586-020-02483-2
  45. Morse B, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2015-000007
  46. Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296
  47. Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344
  48. Mukherjee S., 2021, NEW YORKER
  49. Nuzzo JB, 2020, JAMA-J AM MED ASSOC, V324, P1391, DOI 10.1001/jama.2020.17395
  50. Olsen AL., 2020, WILLINGNESS DISTANCE
  51. Parks CD, 1996, J CONFLICT RESOLUT, V40, P134, DOI 10.1177/0022002796040001007
  52. Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
  53. Perez-Padilla R, 2004, INT J TUBERC LUNG D, V8, P1315
  54. Perez-Padilla R, 2013, SALUD PUBLICA MEXICO, V55, P92, DOI 10.1590/S0036-36342013000100013
  55. Popkin BM, 2020, OBES REV, V21, DOI 10.1111/obr.13128
  56. Prati G, 2011, HEALTH EDUC RES, V26, P761, DOI 10.1093/her/cyr035
  57. PUTNAM RD, 1995, J DEMOCRACY, V0006
  58. R Development Core Team, 2013, R LANG ENV STAT COMP
  59. Ravi SJ, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003648
  60. Razavi A, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002477
  61. Reiner RC, 2021, NAT MED, V27, P94, DOI 10.1038/s41591-020-1132-9
  62. Sorensen RJD, LANCET
  63. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  64. Stolberg SG., 2021, NEW YORK TIMES
  65. Swinburn BA, 2019, LANCET, V393, P791, DOI 10.1016/S0140-6736(18)32822-8
  66. Szreter S, 2004, INT J EPIDEMIOL, V33, P650, DOI 10.1093/ije/dyh013
  67. Taillie LS, 2017, PREV MED, V105, pS37, DOI 10.1016/j.ypmed.2017.07.009
  68. US Centers for Disease Control and Prevention, 2020, SCI BRIEF EV US UPD
  69. Van den Broeck W, 2011, BMC INFECT DIS, V11, DOI [10.1186/1471-2458-11-575, 10.1186/1471-2334-11-37]
  70. Vinck P, 2019, LANCET INFECT DIS, V19, P529, DOI 10.1016/S1473-3099(19)30063-5
  71. Wang H, LANCET
  72. Wang HD, 2020, LANCET, V396, P1160, DOI 10.1016/S0140-6736(20)30977-6
  73. Wu X, 2020, MANAGEMENT TRANSFORMATION OF HUAWEI, P1, DOI 10.1017/9781108550987

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/16